Mundipharma develops and delivers a range of medicines and healthcare solutions, focusing on meeting patient needs. Self-described as having a significant impact on patients.

Mundipharma

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

Bruce Cozadd

Jazz Pharmaceuticals plc

Spirit Medical Group, established in 2005, is a leading supplier to the NHS of IV Therapy fluids, IV administration sets, IV needle-free systems, and other infusion therapy products, as well as a range of high-quality Personal Protection Equipment (PPE). The company is committed to providing the highest quality products and comprehensive clinical training and education, working in partnerships with customers to innovate and respond to the ever-changing needs of healthcare professionals and patients.

Metric
Company Name	Mundipharma	Jazz Pharmaceuticals plc	Spirit Medical Group
Symbol		JAZZ
MSH ID	COM:MUNDIPHARMA	COM:JAZZPHARMA	COM:SPIRITMEDICAL
Market	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services
Industry	Pharmaceuticals	Biotechnology	Healthcare & Health Services
Country	GB	IE
Stage
Employee Count		2.80K	1
Website	mundipharma.com	jazzpharma.com	spiritmedical.com
LinkedIn		jazz-pharmaceuticals
Founders

Metric
Market Cap		6.45B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		3.83B
Revenue (LTM)
Revenue (NTM)
Gross Profit		2.79B
EBITDA		1.30B
Operating Income		659.28M
Net Income		414.83M
EPS		6.55
Diluted EPS		6.10
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.85
Operating Profit Margin		0.17
EBITDA Margin		0.34
Net Profit Margin		0.11
Return on Equity		0.12
Return on Assets		0.04
Return on Capital Employed		0.07

COM:MUNDIPHARMA

Mundipharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		95.39
P/B Ratio		2.21
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		2.03
EV Multiple		2.48

Metric
Days Sales Outstanding		60.39
Days Payables Outstanding		80.89
Days Inventory Outstanding		371.16
Operating Cycle		438.35
Cash Conversion Cycle		374.47
Asset Turnover		0.34

Metric
Operating Cash Flow		1.09B
Free Cash Flow		1.07B
Cash Flow to Debt		0.19
Operating Cash Flow/Sales		0.28
Free Cash Flow Yield		0.11

Metric
Cash & Equivalents		1.21B
Accounts Receivable		-51.88M
Inventory		597.04M
Goodwill		1.75B
Debt to Capitalization		0.61
Debt to Assets		0.52
Current Ratio		2.06
Quick Ratio		2.02

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.06
R&D to Revenue		0.21
SG&A to Revenue